US companies seeking for listings on Hong Kong exchange

Start adding items to your reading lists:

Sign in

or

Create your account

Save this item to:

This item has been saved to your reading list.

In February 2018, the Hong Kong Exchanges and Clearing Limited (“HKEX”) issued a consultation paper seeking public feedback on its proposal to expand the existing listing regime to allow the listing of:

Biotech issuers which are pre-profit/pre-revenue;

Companies from emerging and innovative sectors that have weighted voting rights structures; and

Companies already listed on the NYSE or Nasdaq to seek for secondary listing.

The proposed changes are expected to attract high potential biotech companies as well as already listed companies from around the world to seek for a listing in Hong Kong.

What are some of the topics that US based companies should pay special attention at when considering a Hong Kong listing?